Maggie L. Wong

Maggie L. Wong

Partner
Maggie L. Wong

Maggie Wong, a partner in Goodwin’s Technology Companies & Life Sciences Group, focuses her practice primarily on the life sciences sector. Ms. Wong’s representation of start-up and later-stage companies and their investors spans the entire corporate life-cycle, including pre-incorporation planning, general corporate representation and counseling, venture capital financings, public offerings, SEC compliance, and mergers and acquisitions. She also has substantial experience advising on technology transfer, licensing, partnering, distribution and other commercial agreements.

She is a member of the Associate Training Committee for Goodwin’s Technology Companies & Life Sciences Group and a member of the firm's Impact and Responsible Investing Practice and Associate Adviser Network.

Experience

Ms. Wong often serves as outside general counsel to life science companies as they develop, in-license and acquire intellectual property and other assets, raise capital to fund their operations and seek to partner their technology or engage in exit transactions. She has represented biotechnology, medical device, diagnostics and specialty pharmaceutical companies and their investors on a range of corporate and transactional matters.

Representative Matters

Private Company Financing Transactions
  • aTyr Pharma, Inc. in its $76 million Series E Preferred Stock financing
  • Cleave Biosciences, Inc. in its $54 million Series A Preferred Stock financing and $37 million Series B Preferred Stock financing
  • Delinia, Inc. in its $35 million Series A Preferred Stock financing
  • Global Blood Therapeutics, Inc. in its $40.7 million Series A Preferred Stock financing and $48 million Series B Preferred Stock financing
  • MyoKardia, Inc. in its $46 million Series B Preferred Stock financing
  • Spinifex Pharmaceuticals, Inc. in its $45 million Series C Preferred Stock financing
  • Baird Venture Partners in multiple portfolio investments, including Zurex Pharma Inc. and Insightra Medical Inc.
Public Company Financing Transactions
  • Global Blood Therapeutics in its $120 million initial public offering and $120 million follow-on offering
  • MyoKardia in its $54 million initial public offering and $65 million follow-on offering
  • aTyr Pharma, Inc. in its initial public offering
  • Fate Therapeutics, Inc. in its initial public offering, subsequent follow-on offering and private placement transactions
  • Underwriters in the initial public offering and a subsequent follow-on offering of Regulus Therapeutics Inc.
  • Underwriters in the initial public offering of Conatus Pharmaceuticals Inc.
M&A Transactions
  • Delinia, Inc. in its sale to Celgene Corporation for $300 million upfront and $475 million in milestone payments
  • F-star Alpha Ltd in its exclusive option agreement with Bristol-Myers Squibb for aggregate consideration of up to $475 million
  • Spinifex Pharmaceuticals in its $200 million upfront sale to Novartis International AG plus undisclosed clinical development and regulatory milestones
  • Artisan Pharma, Inc. in its sale to Asahi Kasei Pharma Corp. for an undisclosed amount
  • Assembly Pharmaceuticals, Inc. in its merger with Ventrus Biosciences, Inc. to become Assembly Biosciences, Inc. (NASDAQ: ASMB)
Professional Activities

Ms. Wong is a member of the American Bar Association and the San Francisco Bar Association.

Professional Experience

Prior to joining Goodwin, Ms. Wong was an associate in the corporate practice group at Heller Ehrman LLP, where she focused her practice on the representation of emerging companies. Before that, she was an associate in the business law department at Cooley LLP. During law school, Ms. Wong was a summer intern in the Office of the General Counsel of the U.S. Securities and Exchange Commission in Washington, D.C.

Recognition

Ms. Wong has been recognized by The Legal 500 U.S. for her work in the life science industry. While attending law school, Ms. Wong was a Senior Articles Editor for the Asian Law Journal.

Credentials

Education

J.D., 2002
University of California, Berkeley School of Law

(Order of the Coif)

B.A., 1999
Yale University

(cum laude)

Admissions

Bar

California
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.
Search Other Lawyers